Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.
14-3-3 Proteins
/ cerebrospinal fluid
Age of Onset
Alzheimer Disease
/ cerebrospinal fluid
Amyloid beta-Peptides
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Cerebral Cortex
/ diagnostic imaging
Diffusion Tensor Imaging
Female
Frontotemporal Dementia
/ cerebrospinal fluid
Hippocampus
/ diagnostic imaging
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neurofilament Proteins
/ cerebrospinal fluid
Neurogranin
/ cerebrospinal fluid
Neuroimaging
Peptide Fragments
/ cerebrospinal fluid
tau Proteins
/ cerebrospinal fluid
Alzheimer's disease
Frontotemporal Dementia
biological markers
magnetic resonance imaging
Journal
Human brain mapping
ISSN: 1097-0193
Titre abrégé: Hum Brain Mapp
Pays: United States
ID NLM: 9419065
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
08
07
2019
revised:
11
12
2019
accepted:
04
01
2020
pubmed:
17
1
2020
medline:
9
11
2021
entrez:
17
1
2020
Statut:
ppublish
Résumé
Prior studies have described distinct patterns of brain gray matter and white matter alterations in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), as well as differences in their cerebrospinal fluid (CSF) biomarkers profiles. We aim to investigate the relationship between early-onset AD (EOAD) and FTLD structural alterations and CSF biomarker levels. We included 138 subjects (64 EOAD, 26 FTLD, and 48 controls), all of them with a 3T MRI brain scan and CSF biomarkers available (the 42 amino acid-long form of the amyloid-beta protein [Aβ42], total-tau protein [T-tau], neurofilament light chain [NfL], neurogranin [Ng], and 14-3-3 levels). We used FreeSurfer and FSL to obtain cortical thickness (CTh) and fraction anisotropy (FA) maps. We studied group differences in CTh and FA and described the "AD signature" and "FTLD signature." We tested multiple regression models to find which CSF-biomarkers better explained each disease neuroimaging signature. CTh and FA maps corresponding to the AD and FTLD signatures were in accordance with previous literature. Multiple regression analyses showed that the biomarkers that better explained CTh values within the AD signature were Aβ and 14-3-3; whereas NfL and 14-3-3 levels explained CTh values within the FTLD signature. Similarly, NfL levels explained FA values in the FTLD signature. Ng levels were not predictive in any of the models. Biochemical markers contribute differently to structural (CTh and FA) changes typical of AD and FTLD.
Identifiants
pubmed: 31944489
doi: 10.1002/hbm.24925
pmc: PMC7267898
doi:
Substances chimiques
14-3-3 Proteins
0
Amyloid beta-Peptides
0
Biomarkers
0
MAPT protein, human
0
Neurofilament Proteins
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
neurofilament protein L
0
tau Proteins
0
Neurogranin
132654-77-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2004-2013Subventions
Organisme : European Research Council
ID : 681712
Pays : International
Informations de copyright
© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals, Inc.
Références
Hum Brain Mapp. 2020 Jun 1;41(8):2004-2013
pubmed: 31944489
Am J Alzheimers Dis Other Demen. 2007 Dec-2008 Jan;22(6):474-88
pubmed: 18166607
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Neurology. 2001 Jun 12;56(11):1528-33
pubmed: 11402110
Neurology. 2010 Oct 5;75(14):1249-55
pubmed: 20810999
Neurology. 2000 May 23;54(10):1960-4
pubmed: 10822437
JAMA Neurol. 2019 Mar 1;76(3):318-325
pubmed: 30508027
Alzheimers Res Ther. 2017 Aug 31;9(1):70
pubmed: 28859660
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5
pubmed: 10984517
Neurology. 2016 Mar 1;86(9):829-35
pubmed: 26826204
Acta Neuropathol. 2018 Sep;136(3):363-376
pubmed: 29700597
Neurology. 2017 Jul 11;89(2):178-188
pubmed: 28592456
Brain. 2009 Sep;132(Pt 9):2579-92
pubmed: 19439421
Neurobiol Aging. 2015 Mar;36(3):1261-70
pubmed: 25638532
Neurobiol Aging. 2017 Apr;52:196-213
pubmed: 28317649
Alzheimers Dement. 2015 Oct;11(10):1180-90
pubmed: 25533203
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Neurobiol Aging. 2013 May;34(5):1462-8
pubmed: 23218900
Neurobiol Aging. 2015 Aug;36(8):2340-7
pubmed: 25990306
Ann Clin Transl Neurol. 2018 Sep 20;5(10):1250-1263
pubmed: 30349860
J Alzheimers Dis. 2011;26 Suppl 3:77-90
pubmed: 21971452
J Intern Med. 2014 Apr;275(4):418-27
pubmed: 24237038
Eur J Neurol. 2019 Aug;26(8):1098-1104
pubmed: 30793432
Neurology. 2016 Sep 27;87(13):1329-36
pubmed: 27581216
J Neurol Neurosurg Psychiatry. 2010 Nov;81(11):1243-8
pubmed: 20855493
Neuroimage. 2006 Jul 15;31(4):1487-505
pubmed: 16624579
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Neurobiol Aging. 2017 Jan;49:138-144
pubmed: 27794264
Ann Clin Transl Neurol. 2017 Jun 07;4(7):466-477
pubmed: 28695147
Alzheimers Dement. 2017 May;13(5):499-509
pubmed: 27693189
J Alzheimers Dis. 2010;19(4):1401-8
pubmed: 20061618
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853
pubmed: 31097472
J Intern Med. 2018 Dec;284(6):643-663
pubmed: 30051512
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
Neuroimage Clin. 2015 Sep 09;9:418-29
pubmed: 26594624
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Neuroimage Clin. 2017 May 25;15:428-438
pubmed: 28616383
Clin Chem. 2018 Jun;64(6):927-937
pubmed: 29523639
Ann Neurol. 2014 Jan;75(1):116-26
pubmed: 24242746
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Alzheimers Dis. 2017;59(4):1327-1334
pubmed: 28731449